Trial of the novel peroral anti-tumor treatment in patients with solid tumors

2024-511215-21-00 Protocol TU31-KH1 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 7 Jun 2022 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol TU31-KH1

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 30
Countries 1
Sites 1

Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

Key facts

Sponsor
VUAB Pharma a.s.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
7 Jun 2022 → ongoing
Decision date (initial)
2024-09-09
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-511215-21-00
EudraCT number
2020-005912-23

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Metastatic or locally advanced solid tumors for which no standard therapy exists or standard therapy has failed: tumors of lung, head and neck, colon, stomach, esophagus, breast, ovary and/or fallopian tube or primary peritoneal high-grade serous carcinoma

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

VUAB Pharma a.s.

Sponsor organisation
VUAB Pharma a.s.
Address
Vltavska 53
City
Roztoky
Postcode
252 63
Country
Czechia

Scientific contact point

Organisation
VUAB Pharma a.s.
Contact name
Vladimír Kysilka

Public contact point

Organisation
VUAB Pharma a.s.
Contact name
Vladimír Kysilka

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Czechia Ongoing, recruiting 30 1
Rest of world 0

Investigational sites

Czechia

1 site · Ongoing, recruiting
Masarykuv Onkologicky Ustav
Dptm of Clinical Oncology, Zluty Kopec 543/7, Stare Brno, Brno-Stred

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Czechia 2022-06-07 2022-06-07

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-07 Czechia Acceptable with conditions
2024-09-05
2024-09-09
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-02-11 Czechia Acceptable with conditions
2024-09-05
2025-02-11
3 SUBSTANTIAL MODIFICATION SM-4 2025-08-05 Czechia Acceptable
2025-09-16
2025-10-01